Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis : A systematic review and meta-analysis
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved..
BACKGROUND: Coronavirus disease 2019 (COVID-19) has been the most talked-about disease of the past few years. Patients with significant comorbidities have been at particular risk of adverse outcomes. This study looked at the outcomes and risk factors for adverse outcomes among patients on chronic hemodialysis for end-stage renal disease, a group of patients known to be particularly susceptible to infectious complications.
AIM: To assess outcomes and risk factors for adverse outcomes of COVID-19 infection among patients on chronic hemodialysis.
METHODS: We searched PubMed/MEDLINE, EMBASE, Reference Citation Analysis (https://www.referencecitationanalysis.com/) and Web of Science databases for relevant terms and imported the results into the Covidence platform. From there, studies were assessed in two stages for relevance and quality, and data from studies that satisfied all the requirements were extracted into a spreadsheet. The data was then analyzed descriptively and statistically.
RESULTS: Of the 920 studies identified through the initial database search, only 17 were included in the final analysis. The studies included in the analysis were mostly carried out during the first wave. We found that COVID-19 incidence among patients on hemodialysis was significant, over 10% in some studies. Those who developed COVID-19 infection were most likely going to be hospitalized, and over 1 in 5 died from the infection. Intensive care unit admission rate was lower than the infection lethality rate. Biochemical abnormalities and dyspnea were generally reported to be associated with adverse outcomes.
CONCLUSION: This systematic review confirms that patients on chronic hemodialysis are very high-risk individuals for COVID-19 infections, and a significant proportion was infected during the first wave. Their prognosis is overall much worse than in the general population, and every effort needs to be made to decrease their exposure.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
World journal of virology - 11(2022), 5 vom: 25. Sept., Seite 352-361 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cancarevic, Ivan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 04.10.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.5501/wjv.v11.i5.352 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347042295 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347042295 | ||
| 003 | DE-627 | ||
| 005 | 20231226032902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5501/wjv.v11.i5.352 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM347042295 | ||
| 035 | |a (NLM)36188740 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cancarevic, Ivan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis |b A systematic review and meta-analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Coronavirus disease 2019 (COVID-19) has been the most talked-about disease of the past few years. Patients with significant comorbidities have been at particular risk of adverse outcomes. This study looked at the outcomes and risk factors for adverse outcomes among patients on chronic hemodialysis for end-stage renal disease, a group of patients known to be particularly susceptible to infectious complications | ||
| 520 | |a AIM: To assess outcomes and risk factors for adverse outcomes of COVID-19 infection among patients on chronic hemodialysis | ||
| 520 | |a METHODS: We searched PubMed/MEDLINE, EMBASE, Reference Citation Analysis (https://www.referencecitationanalysis.com/) and Web of Science databases for relevant terms and imported the results into the Covidence platform. From there, studies were assessed in two stages for relevance and quality, and data from studies that satisfied all the requirements were extracted into a spreadsheet. The data was then analyzed descriptively and statistically | ||
| 520 | |a RESULTS: Of the 920 studies identified through the initial database search, only 17 were included in the final analysis. The studies included in the analysis were mostly carried out during the first wave. We found that COVID-19 incidence among patients on hemodialysis was significant, over 10% in some studies. Those who developed COVID-19 infection were most likely going to be hospitalized, and over 1 in 5 died from the infection. Intensive care unit admission rate was lower than the infection lethality rate. Biochemical abnormalities and dyspnea were generally reported to be associated with adverse outcomes | ||
| 520 | |a CONCLUSION: This systematic review confirms that patients on chronic hemodialysis are very high-risk individuals for COVID-19 infections, and a significant proportion was infected during the first wave. Their prognosis is overall much worse than in the general population, and every effort needs to be made to decrease their exposure | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a End stage kidney disease | |
| 650 | 4 | |a Infection | |
| 650 | 4 | |a Maintenance hemodialysis | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Systematic review | |
| 700 | 1 | |a Nassar, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Daoud, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Hatem |e verfasserin |4 aut | |
| 700 | 1 | |a Nso, Nso |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez, Angelica |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Avish |e verfasserin |4 aut | |
| 700 | 1 | |a Ul Hosna, Asma |e verfasserin |4 aut | |
| 700 | 1 | |a Devanabanda, Bhavana |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Nazakat |e verfasserin |4 aut | |
| 700 | 1 | |a Soliman, Karim M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of virology |d 2012 |g 11(2022), 5 vom: 25. Sept., Seite 352-361 |w (DE-627)NLM232149992 |x 2220-3249 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:5 |g day:25 |g month:09 |g pages:352-361 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5501/wjv.v11.i5.352 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 5 |b 25 |c 09 |h 352-361 | ||